Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2008

View Archived Issues

Positive first-in-human results of Novartis' ATF-936 for the treatment of osteoporosis

Glucosamine analogue GN-1 has in vivo antiarthritic activity

Peptide vaccine ATX-MS-1467 safe and well tolerated in MS patients

Benefit of alefacept in moderate to severe atopic eczema

A.P. Pharma highlights positive phase III APF-530 results in preventing CINV

VaxInnate advances second flu vaccine candidate into clinical development

Prasugrel NDA review not yet completed

Indevus and FDA agree on data requirement for Nebido resubmission

Indevus and Teva sign agreement for pagoclone

IND submission for HA-Irinotecan

Shionogi extends HuCAL license agreement with MorphoSys

Cancer Research UK and Astex to develop new cancer treatment

Daiichi delays Japanese launch of pediatric influenza vaccine ActHIB until December 2008

FDA extends PDUFA action date for Ipsen's BLA for Dysport in cervical dystonia

Astellas submits sNDA to Japanese PMDA for Prograf in myasthenia gravis

Novel antiinfective agents disclosed in recent MicuRx and GSK patents

European Commission grants orphan drug status to Enzon's Oncaspar-IV

Recent Tibotec patents report novel therapeutic agents for HCV infection

New agents for treating neurological disorders disclosed in recent patent literature

Bayer's novel anticoagulant Xarelto receives European approval

European Commission adopts EMEA recommendations for Arcoxia 90 mg

Idera reports preliminary data from phase IIa IMO-2055 trial in RCC

Lilly initiates second global phase III trial for LY-450139 in AD

Ore Pharmaceuticals initiates clinical trial of ACE2 enzyme inhibitor GL-1001

R&D highlights from the UBS Global Life Sciences Conference in New York: Sangamo BioSciences

Tranzyme presents positive phase IIb results for ghrelin agonist TZP-101

Uric acid, a novel therapeutic approach in the treatment of acute stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...